Abstract: The present invention is related to a process for the conversion of used cooking oil into aromatics (BTEX) hydrocarbon as petrochemical building blocks. The process provides an aromatic rich hydrocarbon from used cooking oil in the presence and absence of steam/hydrogen over supported bimetallic alumina-silicates zeolites. The catalyst contains no precious metal entities and may contain one metal form zinc (Zn), a second metal (X), comprising at least one selected from cobalt (Co), gallium (Ga), chromium (Cr), Iron (Fe) and third elements from cerium (Ce), boron (B) supported on alumina-silicates zeolites. The present invention relates to a catalyst excluding novel metals to produce aromatics in a continuous fixed bed reactor system under atmospheric pressure. More particularly, the present invention relates to a low-temperature process to produce aromatic over alumina-silicates zeolites. The process provides used cooking oil conversion of 84-89% with aromatic selectivity of 87-91%.

Abstract: A process for dimerizing and oligomerizing olefins to distillate fuels which manages the dimerization exotherm by diluting it with paraffins which are inert in the dimerization. The olefin stream can also be split and fed to multiple dimerization reactors to further reduce the heat generated. The ethylene feed can also be cooled before entering the dimerization reactor. The paraffins can be obtained from saturating oligomerized effluent.

Abstract: A process (100) for the production of linear alpha-olefins is proposed, wherein ethylene in a feed mixture is subjected to catalytic oligomerization (1) to obtain a product mixture containing alpha-olefins with different chain length and side compounds. In a primary fractionation (2), a primary fraction is formed using at least part of the product mixture, and in a secondary fractionation (4), a secondary fraction is formed using at least part of the primary fraction. The primary fractionation (2) and the secondary fractionation (4) are carried out such that the primary fraction and the secondary fraction predominantly contain one of the alpha-olefins and are low in or free of other alpha-olefins, that the primary fraction contains one or more of the side compounds, and that the secondary fraction is depleted relative to the primary fraction in the one or more side compounds.

Abstract: A method of producing carbon tetrachloride includes providing a chloromethanes stream, combining the chloromethanes stream with chlorine and additional carbon tetrachloride to form a reaction mixture, wherein the reaction mixture includes at least stoichiometric levels of chlorine, introducing electromagnetic radiation to the reaction mixture and subjecting the reaction mixture to suitable reaction conditions to form product carbon tetrachloride, and collecting a product stream including the product carbon tetrachloride.

Abstract: A dehydrohalogenation product includes a hydrochlorofluorocarbon mixture of a fluoroolefin of formula RCX=CZQ and a halofluoroalkane of formula RCXYCZQT. R is a perfluorinated alkyl group and X, Z, and Q are independently H or halogen. One of Y and T is H and the other is Cl, Br, or I. About 80% or greater of the hydrochlorofluorocarbon mixture is the fluoroolefin. The dehydrohalogenation product also includes a caustic agent and a solvent. In some embodiments, the dehydrohalogenation product is free of any catalyst, including any phase transfer catalyst.

Abstract: The present invention relates to a process for the purification of fluorinated olefins, in particular hexafluoro-1,3-butadiene, comprising a step wherein a liquid mixture comprising hexafluoro-1,3-butadiene in liquid phase is contacted with at least one adsorbent having an average pore size of less than 10 ?.

Abstract: The invention concerns an oleyl alcohol, wherein the oleyl chain is obtained from a mixture of 1:9 to 6:4, preferably 2:8 to 5:5 of oil (1):oil (2) by hydrogenation of a fatty acid, a fatty acid methyl ester or a combination thereof to provide a fatty alcohol, where oil (1) is selected from palm oil, cottonseed oil or a mixture thereof, and oil (2) is selected from tall oil, olive oil, low erucic rapeseed oil, sunflower seed oil variants containing greater than 60 wt. % oleic acid or mixtures thereof; and a process to make said oleyl alcohol.

Abstract: Provided is a method which is for producing methanol and which achieves high catalyst stability over time. This method for producing methanol includes the step of bringing a raw material gas into contact with a catalyst to obtain methanol, the raw material gas containing a carbon oxide and hydrogen, the catalyst containing (i) copper and zinc at a molar ratio of the zinc relative to the copper (Zn/Cu) of 0.3 to 0.45, and (ii) an alkali metal in an amount of 0% by mass to 0.05% by mass.

Abstract: A process for converting steam cracking products into an alcohol composition consisting essentially of 2-propanol and butanols is disclosed. The process includes steam cracking and recovery of a stream including propene and butenes, which are next converted catalytically in the presence of water to 2-propanol and butanols respectively.

Abstract: The present invention relates to an integrated process for simultaneously preparing at least two mixtures comprising alkali metal methoxide and methanol in at least two parallel reactive distillation columns, wherein one rectification column is used for providing a methanol stream which is then used as methanol source for the reactive distillation columns, and wherein the top streams of said reactive distillation columns are used as methanol source for said rectification column.

Abstract: A method for purifying phenol can include contacting a first stream containing phenol with a second stream containing wastewater from a bisphenol-A (BPA) production process to form a third stream, distilling the third stream to form a fourth stream containing phenol and water, contacting the fourth stream with a fifth stream containing mother liquor from a BPA crystallization unit of the BPA production process to form a sixth stream, and distilling the sixth stream to form a products stream containing phenol.

Abstract: A method for producing 3,5,5-trimethylhexanal by allowing diisobutylene (DIB), carbon monoxide and hydrogen to react with one another in the presence of a cobalt-based catalyst, comprising: a step of allowing DIB to react with carbon monoxide and hydrogen in the presence of a cobalt-based catalyst until a convention of DIB reaches 50 to 85% (first stage reaction step); a step of separating unreacted DIB from a reaction product obtained in the first stage reaction step (unreacted DIB separation step); and a step of allowing the unreacted DIB separated to react with carbon monoxide and hydrogen in the presence of a cobalt-based catalyst (second stage reaction step).

Abstract: The invention relates to processes for preparing carbaprostacyclin analogues and intermediates prepared from the processes. The invention also relates to cyclopentenone intermediates in racemic or optically active form.

Abstract: Provided is a method for preparing an acrylic acid including: supplying a lactic acid aqueous solution to a reactor and performing a dehydration reaction to prepare a reaction product including an acrylic acid; supplying a reactor discharge stream including the reaction product to a first cooling tower and supplying an upper discharge stream from the first cooling tower to a second cooling tower; supplying a first acrylic acid aqueous solution stream discharged from a lower portion of the second cooling tower to an extraction column; supplying an upper discharge stream from the extraction column and a second acrylic acid aqueous solution stream discharged from a lower portion of the first cooling tower to a distillation column; and separating the acrylic acid from a lower discharge stream from the distillation column.

Abstract: Provided is a method for preparing an acrylic acid, in which a lactic acid aqueous solution is dehydrated to prepare a reaction product stream, from which by-products are removed using an extraction column, an extractant recovery column, a first separation column, a second separation column, and a refining column to prepare a high-purity acrylic acid.

Abstract: The present invention provides a method capable of sufficiently reducing impurities with excellent separation efficiency even from a crystal-containing slurry that contains a low-purity mother liquor and has poor solid-liquid separation properties. The present invention relates to a method for producing a compound, the method including: a step of feeding a slurry containing crystals of the compound to a hydraulic wash column; a step of melting crystals in a crystal-containing circulation slurry discharged from the hydraulic wash column; and a step of returning a portion of a circulation liquid containing a melt obtained in the melting step to the hydraulic wash column, wherein the circulation liquid returned in the returning step in an amount of more than 30% by mass relative to 100% by mass of the melt serves as a washing liquid for crystals.

Abstract: The invention relates to ferulic acid granules and the production method thereof. The invention is suitable for use in particular in the fields of food, cosmetics and flavours.

Abstract: A method for producing 7-methyl-3-methylene-7-octenal of Formula (2) is provided and includes a step of hydrolyzing a 7-methyl-3-methylene-7-octenal acetal compound of General Formula (1): wherein R1 and R2, which may be the same or different, are each analkyl group having 1 to 6 carbon atoms, or are bonded to each other to form a divalent alkylene group having 2 to 12 carbon atoms to obtain the 7-methyl-3-methylene-7-octenal (2).

Abstract: The ester compound of the present invention is represented by the following formula (1), wherein R1 to R24 are each independently a hydrogen atom, a halogen atom, a hydrocarbon group, or a hetero atom-containing hydrocarbon group; R1 to R10, R23, and R24 may be bonded to one another to form a ring or may form a multiple bond at which adjacent substituents are directly bonded; R11 to R24 may be bonded to one another to form a ring, or adjacent substituents may be bonded to one another to form a multiple bond; at least one set in R1 to R24 is bonded to one another to form a ring structure; n2 to n5 each independently represent an integer of 0 to 2; n1 and n6 each independently represent an integer of 0 or 1; and L1 and L2 are each independently a hydrocarbon group or a hetero atom-containing hydrocarbon group.

Abstract: The present invention provides a method of making an enantiomerically enriched tertiary or quaternary ammonium salt, and the use of a non-racemic chiral compound in the synthesis of an enantiomerically enriched tertiary or quaternary ammonium salt. The control of nitrogen-based chirality, achieved via the method of the invention, is useful where a specific tertiary or quaternary ammonium enantiomer is preferred over the other enantiomer, for example where a specific tertiary or quaternary ammonium enantiomer is more effective than the other enantiomer in treating a specific medical condition.

Abstract: A compound represented by Chemical Formula 1 and an organic light emitting device are provided. The compound is used as a material for an organic material layer of the organic light emitting device and provides improved efficiency, low driving voltage and enhanced lifetime.

Abstract: The presently claimed invention relates to a method for obtaining crystalline diethylamino hydroxybenzoyl hexyl benzoate. Further, the presently claimed invention relates to crystalline diethylamino hydroxybenzoyl hexyl benzoate obtained by the method and to a cosmetic composition comprising crystalline diethylamino hydroxybenzoyl hexyl benzoate. The crystalline diethylamino hydroxybenzoyl hexyl benzoate obtained by the method of the presently claimed invention has a phthalic acid dihexyl ester (PSDHE) content in the range of 1 to 250 ppm.

Abstract: A composition comprises one or more trimesic acid derivatives of Formula (I) in which R1, R2, and R3 are independently selected from the group consisting of alkyl groups. A polymer composition comprises a composition as described above and a polyolefin polymer. The polymer compositions containing a trimesic acid derivative of Formula (I) exhibit very low haze levels and minimal extraction of the trimesic acid derivative.

Abstract: In one aspect, the disclosure relates to methods for preparation of terpene and terpene-like molecules. In a further aspect, the disclosure relates to the products of the disclosed methods, i.e., terpene and terpene-like molecules prepared using the disclosed methods. Intermediates for the synthesis of a wide variety of terpenoids are ?-allyl Knoevenagel adducts or quasi ?-allyl Knoevenagel adducts are disclosed. In various aspects, methods of preparing terpenoids through these intermediates are disclosed. The methods can comprise ?-alkylation of an allylic electrophile followed by ring-closure metathesis to a polycyclic terpenoid structure. In a further aspect, the disclosure pertains to terpenoid frameworks, and compounds prepared via disclosed oxidation and substitution reactions on the disclosed terpenoid frameworks. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Abstract: The present disclosure relates to phenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), such as agonism of the FPR1 and/or FPR2 receptor, or selective agonism of the FPR1 receptor relative to the FPR2 receptor.

Abstract: Provided is a metastasis-inhibiting composition containing a methylsulfonamide-based derivative compound as an active ingredient. More specifically, the compounds inhibit the activity of chromosome segregation 1-like (CSE1L), and suppress intracellular nuclear transport to inhibit the movement and/or invasion of cancer cells, and thus effectively inhibit metastasis.

Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.

Abstract: The present invention concerns a method for sulfhydrolysis from dialkyl sulfides and hydrogen sulfide, in the presence of a specific catalyst based on titanium dioxide and/or zirconium dioxide, as well as the corresponding use of such a catalyst. The present invention also concerns a method for preparing mercaptans, in particular methyl mercaptan, from at least one alcohol and hydrogen sulfide, comprising said sulfhydrolysis method.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: The invention relates to compounds useful as inhibitors of NO production, especially inhibitors of the inducible NO synthase iNOS expressed by microglia and macrophages. The invention also relates to pharmaceutical compositions comprising these compounds and to therapeutic uses of these compounds, especially in the prophylaxis or treatment of conditions characterized by excess NO production, such as ischemic stroke and retinopathies.

Abstract: The disclosure relates to a compound of formula (I): The disclosure also relates to a compound of formula (Ia): The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).

Abstract: Provided herein are compounds and compositions thereof for modulating BCL6. In some embodiments, the compounds and compositions are provided for treatment of cancer or an autoimmune disease.

Abstract: The present invention is directed to, in part, deuterium-enriched compounds and compositions comprising a deuterium-enriched compound useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel.

Abstract: Disclosed are compounds of Formula 1, N-oxides of the compounds and salts of the compounds and N-oxides: wherein R1, R2, R3, R4, R5, R6, Q1, Q2, J, Y1, and Y2 are as defined in the disclosure. Also disclosed are compositions containing the compounds, N-oxides and salts, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of such a compound. N-oxide, salt or composition.

Abstract: The present invention relates to a compound of formula (I). It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the use of such a compound as a medicine, preferably in the treatment of a nervous and/or respiratory failure due to intoxication with at least one organophosphorous nerve agent; in the treatment of neurological diseases such as Alzheimer's disease; and/or in the treatment of cancer.

Abstract: The present invention relates to a crystalline modification of Modoflaner 6-fluoro-N-(3-(2-iodo-4-(perfluoropropan-2-yl)-6-(trifluoromethyl)phenylcarbamoyl)-2-fluorophenyl)nicotinamide of formula (I):

Abstract: The present invention relates to novel compounds of formula (Ia), to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of YAP/TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present invention also relates to processes for the preparation of said compounds.

Abstract: The present invention provides sulfamate derivative prodrugs of the dopamine agonist (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, their use in the treatment of conditions for which treatment with a dopamine agonist is therapeutically beneficial and pharmaceutical compositions comprising compounds of the invention. Compounds according to the invention are of formula (Id), wherein R1 and R2 are each independently selected from H, and substituent (iii) below, wherein * indicates the attachment point to oxygen, wherein R3 is selected from H and COR4, and wherein R4 is selected from H and C1-C6 alkyl, with the proviso that R1 and R2 cannot both be H,15 or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a group of novel compounds, methods for their manufacture and the use of these compounds as research tools and as pharmaceuticals. The novel compounds are analogues of cannabidiol (CBD). CBD is a non-psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of novel cannabidiol compounds.

Abstract: The invention in this disclosure is related to the processes of making Bindarit or derivatives thereof. Specifically, the present invention provides, in part, new processes for making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives. By way of non-limiting example, synthesis and purification processes of 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid are provided by the invention in this disclosure.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.

Abstract: The invention generally relates to methods of coupling a carbon containing moiety to an amine containing moiety.

Abstract: Substituted N-phenyluracils and salts thereof and use thereof as herbicidal agents. The present invention relates to substituted N-phenyluracils of the general formula (I) or salts thereof, where the radicals in the general formula (I) conform to the definitions given in the description, and to the use thereof as herbicides, especially for control of broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants.

Abstract: Provided herein are SOS1 protein degraders, for example, a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an SOS1-mediated disorder, disease, or condition.

Abstract: A method for preparing 3,6-diaminopyrazine-2,5-dicarboxylic acid and a synthetic intermediate thereof. The method comprises the step of preparing pyrimido[4,5-g]pteridine-2,4,7,9(1H,3H,6H,8H)-tetraone or a disalt (pteridine) thereof from 5-aminouracil or a single salt thereof.

Abstract: The present invention is directed to a process for the preparation of a hydrazine derivative by reaction of the corresponding oxirane with hydrazine, that uses as only solvent toluene. The process provides excellent yields and purities and allows to proceed without purification in a one-pot scheme. Toluene additionally reduces the excess of hydrazine needed to complete the reaction, significantly reducing the waste treatment costs and even allows the hydrazine to be recycled into the reaction.

Abstract: The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligands having a glutamate-urea-lysine (GUL) moiety and a chelating agent that can comprise a radiometal.

Abstract: A process for producing a benzoxazine containing free aliphatic hydroxyl groups and monoester comprising the steps of: a) a reaction of a phenolic acid derivative with a monofunctional oligomer or molecule at a temperature of from 80° C. to 200° C., during 12 h-48 h, in a presence of a Bronsted type acid catalyst, resulting in a monophenol terminated oligomer or molecule and b) reaction of the monophenol terminated oligomer or molecule of step a) with a mixture of an amino-alcohol, a primary amine derivative and paraformaldehyde at a temperature range of from 80° C. to 100° C., from 1 h to 48 h, under stirring.

Abstract: Disclosed are phenothiazine compounds which reduce Abeta toxicity in vivo, reduce microglial inflammation as indicated by secretion of TNF-alpha, reduce intracerebral hemorrhage in vivo toxicity as indicated by preserved motor and cognitive function, and SARS-CoV-2 replication. Also disclosed are methods of use thereof for the treatment of disease in a subject in need thereof.

Abstract: A process for the epoxidation of ethylene comprising: contacting an inlet feed gas comprising ethylene, oxygen and one or more reaction modifiers consisting of organic chlorides with an epoxidation catalyst comprising a carrier, and having silver, a rhenium promoter, and one or more alkali metal promoters deposited thereon; wherein the inlet feed gas has an overall catalystchloriding effectiveness value (Cleff) represented by the formula (I): wherein [MC], [EC], [EDC], and [VC] are the concentrations in ppmv of methyl chloride (MC), ethylchloride (EC), ethylene dichloride (EDC), and vinylchloride (VC), respectively, and [CH4], [C2H6] and [C2H4] are the concentrations in mole percent of methane, ethane, and ethylene, respectively, in the inlet feedgas; wherein at a cumulative ethylene oxide production cumEO1 of at least 0.